AGEX THERAPEUTICS INC (AGE) Stock Overview
NYSEARCA:AGE - US00848H2076 - Common Stock
AGE Key Statistics, Chart & Performance
The current stock price of AGE is 11.1 USD. In the past month the price decreased by -19.01%. In the past year, price decreased by -52.4%.
AGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.00B | ||
| AMGN | AMGEN INC | 13.47 | 157.94B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 63.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.78 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.61B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About AGE
Company Profile
AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The firm's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.
Company Info
AGEX THERAPEUTICS INC
1101 Marina Village Parkway, Suite 201
Alameda CALIFORNIA 94501 US
CEO: Michael D. West
Employees: 5
Phone: 15106718370
AGEX THERAPEUTICS INC / AGE FAQ
What is the stock price of AGEX THERAPEUTICS INC today?
The current stock price of AGE is 11.1 USD. The price decreased by -11.9% in the last trading session.
What is the ticker symbol for AGEX THERAPEUTICS INC stock?
The exchange symbol of AGEX THERAPEUTICS INC is AGE and it is listed on the NYSE Arca exchange.
On which exchange is AGE stock listed?
AGE stock is listed on the NYSE Arca exchange.
What is AGEX THERAPEUTICS INC worth?
AGEX THERAPEUTICS INC (AGE) has a market capitalization of 421.25M USD. This makes AGE a Small Cap stock.
How many employees does AGEX THERAPEUTICS INC have?
AGEX THERAPEUTICS INC (AGE) currently has 5 employees.
What are the support and resistance levels for AGEX THERAPEUTICS INC (AGE) stock?
AGEX THERAPEUTICS INC (AGE) has a resistance level at 22.04. Check the full technical report for a detailed analysis of AGE support and resistance levels.
Should I buy AGEX THERAPEUTICS INC (AGE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AGE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AGE, evaluating the profitability, health, valuation and growth aspects
- AGEX THERAPEUTICS INC (AGE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AGEX THERAPEUTICS INC (AGE) Sales and EPS estimates to see what analysts future expectations are.
- AGEX THERAPEUTICS INC (AGE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AGEX THERAPEUTICS INC (AGE) Insider and Institutional Ownership to learn about the owners and their transactions.
- AGEX THERAPEUTICS INC (AGE) Stock Chart to make your own analysis
- AGEX THERAPEUTICS INC (AGE) Latest news and press-releases to stay up to date.
Does AGEX THERAPEUTICS INC (AGE) stock pay dividends?
AGE does not pay a dividend.
When does AGEX THERAPEUTICS INC (AGE) report earnings?
AGEX THERAPEUTICS INC (AGE) will report earnings on 2024-05-13, after the market close.
What is the Price/Earnings (PE) ratio of AGEX THERAPEUTICS INC (AGE)?
AGEX THERAPEUTICS INC (AGE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
AGE Technical Analysis
AGE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGE. AGE has a bad profitability rating. Also its financial health evaluation is rather negative.
AGE Financial Highlights
Over the last trailing twelve months AGE reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -42.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.07% | ||
| ROE | -166.86% | ||
| Debt/Equity | 0.08 |